AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

OPRX · NASDAQ · Medical - Healthcare Information Services

OptimizeRx

Connects life-sciences marketers, clinicians, and patients through prescribing, engagement, and consumer-audience tools.

$7.95

After-hours close0.00 (0.00%)

At close$7.95(+1.53%)

Something off on this page? Send us feedback.

Profile

OptimizeRx CorporationOPRXHealth Care

Offers digital tools that connect life-sciences marketers with health-care professionals and patients through EHR and e-prescribing workflows. The business has expanded from co-pay messaging into patient engagement, specialty prescribing, and privacy-oriented consumer audience activation.

Connects life-sciences companies, health-care professionals, and patients through workflow-embedded communications. Its original service placed coupon and co-pay assistance messages inside EHR and e-prescribing systems. CareSpeak added direct patient interactive health messaging, while EvinceMed added a platform for specialty-pharmaceutical transactions among manufacturers, hub providers, and pharmacies.

Consumer-audience capabilities added through Medicx pair omnichannel marketing and analytics with a health-care-professional-oriented platform. Current materials describe the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT), which uses privacy-safe, geography-based targeting rather than identified patients. The business is rooted in health-care workflows and patient communications.

Company facts

CEOStephen L. Silvestro

ListedNov 28, 2007

ExchangeNASDAQ

HeadquartersWaltham, MA

CountryUnited States

Employees133

CIK0001448431

ISINUS68401U2042

Key statistics

Market cap$149.2M

EPS (ttm)$0.2336

P/E (ttm)34.03

ROE3.6%

P/B1.14

P/S1.51

Dividend yield—

Beta2.00vs XLV 0.39

Year to date −36.0% · Average volume (30d) 234.5K

Analysts

Price target, next 12 months$11.00+38.4%Median of 15 analysts · vs the Aug 28 close

ConsensusBuy11 of 15 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.95

High$12.00+50.9%

Median$11.00+38.4%

Low$7.00−11.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 14, 2026	UBS	Target		$10	$11
Aug 13, 2026	Stifel Nicolaus	Target		$14	$12
May 13, 2026	UBS	Target		$23	$10
May 13, 2026	Lake Street	Reiterate	Buy		$11
May 13, 2026	Stephens	Target			$7

Earnings

EPS

Estimate$0.19

ReportedDue Nov 5, 2026

Revenue

Estimate$21.6M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	$0.11	$0.16	+44.0%	$20.2M	$20.5M	+1.5%	+24.72%
May 12, 2026Q1 FY26	$0.01	$0.14	+1,300.0%	$18.7M	$19.8M	+5.9%	−22.40%
Mar 5, 2026Q4 FY25	$0.23	$0.51	+121.7%	$30.9M	$32.2M	+4.3%	−10.49%
Nov 6, 2025Q3 FY25	$0.03	$0.20	+566.7%	$30.9M	$26.1M	−15.7%	−17.37%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$21.9M	$29.2M	$26.1M	$32.2M	$19.8M	$20.5M
Gross profit	$13.3M	$18.6M	$17.5M	$24.1M	$13.9M	$15.7M
Operating income	−$2.1M	$3.2M	$2.0M	$8.9M	$396.0K	−$88.0K
Net income	−$2.2M	$1.5M	$779.0K	$5.0M	−$495.0K	−$703.0K
Diluted EPS	−$0.12	$0.08	$0.04	$0.26	−$0.03	−$0.04
Gross margin	60.9%	63.8%	67.2%	74.8%	69.9%	76.5%
Operating margin	-9.6%	10.9%	7.9%	27.7%	2.0%	-0.4%

Fiscal years (4-quarter sums)FY21 $61.3M · FY22 $62.5M · FY23 $71.5M · FY24 $92.1M · FY25 $109.4M

Revenue by product · FY25

Other Revenue$215.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $24.1M · Total debt $19.5M · Total assets $164.3M · Shareholders' equity $131.1M

Dividends

No dividends on record.

Ownership

Institutions 59.81%11.22M sharesInsiders 7.46%1.40M sharesOther 32.73%6.14M shares

Shares outstanding 18.77M · Float 14.43M · 76.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Whetstone Capital Advisors, LLC	1.51M	8.04%	13F	Aug 14, 2026
Kennedy Capital Management LLC	1.25M	6.70%	13G	Aug 14, 2026
Royce & Associates LP	1.09M	5.81%	13G	Jul 22, 2026
Andrew N. Wiener	1.04M	5.70%	13G	Nov 13, 2024
Vanguard Capital Management LLC	699.6K	3.73%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Dec 19, 2025	Edward Stelmakh	officer: Chief Finance & Strat Officer	−1,388	$13.51
Oct 3, 2025	Stephen L. Silvestro	officer: Chief Executive Officer	−1,620	$18.75
Aug 28, 2025	Patrick D. Spangler	director	−11,120	$17.49